Active COVID-19 Clinical Trials at NMH

Drug	Study Design	Intervention	Inclusion Criteria	Key Exclusion Criteria	Patient Enrollment
(ACTT-3) **Remdesivir (GS-5734)** *Antiviral* **Interferon beta-1a (Rebif)** *Biological Response Modulator*	▪ Randomized ▪ (1:1 ratio) ▪ Blinded (remdesivir is open label, while interferon beta-1a is blinded) Adaptive COVID-19 Treatment Trial to evaluate the clinical efficacy of different Investigational therapeutics as compared to the control arm. (NCT04492475)	**Arm 1**: remdesivir (daily x 5 or up to 10 days; to be determined by PI) **Plus** interferon beta-1a 44 mcg (subcutaneous) daily for 4 doses OR **Arm 2**: remdesivir (daily x 5 or up to 10 days; to be determined by PI) **Plus** placebo	▪ Hospitalized ▪ Age ≥ 18 years old ▪ Confirmed COVID (PCR or other approved method): – Within < 72 hours – Or > 72 hours but < 7 days if with progressive disease suggestive of active COVID (radiographically, O2< 94% on RA or requiring supplemental O2 (including ventilator)	▪ Not on ECMO ▪ eGRF < 30 ml/min (PI may weigh in) ▪ ALT or AST > 5 x ULN ▪ WBC < 1500 cells/uL ▪ Platelet < 50K ▪ Not in another COVID trial within last 29 Days ▪ Had > 2 doses of remdesivir EUA ▪ Concomitant chloroquine or hydroxychloroquine is contraindicated ▪ Patient cannot receive any other COVID treatment, monoclonal antibodies, convalescent plasma or IVIG	COVID ID pager 26651 PI: Babafemi Taiwo Study coordinator: Johnny Perez 312-707-7403
Trial enrollment at NMH is currently OPEN					